;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Cortendo pulls Oslo IPO to mull U.S. listing, raises $11.3M

    Cortendo AB (Gothenburg, Sweden) said it will raise SEK 81.5 million ($11.3 million) in a private placement. The company will also drop plans to list on the Oslo Axess exchange and consider a U.S. listing instead.The …

    Published on 10/30/2014
  • FINANCIAL NEWS: FibroGen targeting near-billion dollar valuation

    FibroGen Inc. (San Francisco, Calif.) set terms for its IPO on NASDAQ and plans to sell 7.1 million shares at $16-$19. At $17.50, the company would raise $124.3 million and be valued at $974.3 million. Goldman Sachs; …

    Published on 10/30/2014
  • FINANCIAL NEWS: Incyte jumps on Jakafi trajectory

    Incyte Corp. (NASDAQ:INCY) jumped $6.31 (11%) to $64.18 on Thursday after its 3Q14 earnings beat Street expectations, including a 63% increase in Jakafi ruxolitinib sales compared to 3Q13.Jakafi, sold outside the U.S. …

    Published on 10/30/2014
  • FINANCIAL NEWS: Pacira dinged on Exparel "disruptions"

    Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) fell $14.70 (14%) to $91.11 on Thursday as investors digested comments on the company's earnings call related to a previously announced September warning letter from FDA about …

    Published on 10/30/2014
  • FINANCIAL NEWS: Rhythm withdraws IPO after Actavis deal

    Rhythm Pharmaceuticals Inc. (Boston, Mass.) withdrew its proposed IPO on NASDAQ. Last week, the company received $40 million up front in a deal giving Actavis plc (NYSE:ACT) an option to acquire a Rhythm subsidiary that…

    Published on 10/30/2014
  • FINANCIAL NEWS: Chimerix planning $105M follow-on

    Chimerix Inc. (NASDAQ:CMRX) said it plans to raise about $105 million in a follow-on underwritten by Morgan Stanley; JP Morgan; Cowen; Piper Jaffray; and Stifel, Nicolaus.Chimerix's brincidofovir is in Phase III trials …

    Published on 10/29/2014
  • FINANCIAL NEWS: Regulus raises $75M in follow-on

    Regulus Therapeutics Inc. (NASDAQ:RGLS) wasted little time cashing in on a recent stock surge, as the microRNA company raised $75 million through the sale of 4.4 million shares at $17 in a follow-on underwritten by …

    Published on 10/29/2014
  • FINANCIAL NEWS: Synergy raises $175M in note deal

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) raised $175 million through the sale of senior unsecured convertible notes. The notes bear 7.5% interest, mature in 2019 and initially convert at $3.11. Synergy's lead compound…

    Published on 10/29/2014
  • FINANCIAL NEWS: Vanda raises $58M in follow-on

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) raised $58 million through the sale of 5 million shares at $11.60 in a follow-on underwritten by Jefferies; Piper Jaffray; JMP Securities; and Canaccord. The neurology company …

    Published on 10/29/2014
  • FINANCIAL NEWS: Diabetes, not CEO, dominates Sanofi earnings

    American depository shares of Sanofi (Euronext:SAN; NYSE:SNY) fell $4.75 to $48.07 in New York on Tuesday as the company revealed that sales in its diabetes franchise would be flat in 2015 primarily because of …

    Published on 10/28/2014
  • FINANCIAL NEWS: SynCore raises $19.4M in Taiwanese IPO

    SynCore Biotechnology Co. Ltd. (GreTai-E:4192) lost NT$15.90 (18%) to NT$70.10 in its first day of trading Tuesday after raising NT$590.6 million ($19.4 million) through the sale of 6.8 million shares at NT$86 in an IPO…

    Published on 10/28/2014
  • FINANCIAL NEWS: Advent closes new fund with L145.5M

    European VC firm Advent Venture Partners closed Advent Life Sciences Fund II with L145.5 million ($234.3 million). The fund came from new and existing LPs, including funds-of-funds, pension funds and family offices.…

    Published on 10/27/2014
  • FINANCIAL NEWS: Amgen boosts guidance ahead of business review

    Amgen Inc. (NASDAQ:AMGN) reported 3Q14 non-GAAP EPS of $2.30 and revenues of $5 billion, which beat the Street and represented 19% and 6% growth over 3Q13, respectively. The company also raised its 2014 guidance on …

    Published on 10/27/2014
  • FINANCIAL NEWS: Syros closes $53M series B for super-enhancers

    Syros Pharmaceuticals Inc. (Watertown, Mass.) raised $53 million in a series B round led by an undisclosed Boston-based public investment firm. Polaris Partners; Aisling Capital; and Redmile Group invested for the first…

    Published on 10/27/2014
  • FINANCIAL NEWS: Angion withdraws IPO

    Angion Biomedica Corp. (Uniondale, N.Y.) withdrew its proposed IPO on NASDAQ, citing market conditions. In June, the company amended its IPO to sell 2.7 million shares at $10-$12. At $11, the company would have raised $…

    Published on 10/24/2014
  • FINANCIAL NEWS: Coherus sets IPO terms

    Biosimilars developer Coherus Biosciences Inc. (Redwood City, Calif.) set terms for its IPO on NASDAQ and plans to sell 6.3 million shares at $12-$15. At $13.50 Coherus would raise $85 million and be valued at $432.7 …

    Published on 10/24/2014
  • FINANCIAL NEWS: Alexion, BioMarin raise 2014 guidance

    Rare disease specialists Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) both raised 2014 guidance in earnings reports on Thursday.Alexion shares added $12.65 to $185.92 after …

    Published on 10/23/2014
  • FINANCIAL NEWS: Erytech raises EUR 30M in follow-on

    Erytech Pharma S.A. (Euronext:ERYP) raised EUR 30 million ($38.2 million) through the sale of 1.2 million shares at EUR 24.50 in a follow-on. U.S. investors provided 68% of the funds.Erytech will use the money to …

    Published on 10/23/2014
  • FINANCIAL NEWS: Probiodrug raises EUR 22.5M in IPO

    Probiodrug AG (Euronext:PBD) raised EUR 22.5 million ($28.7 million) in an IPO through the sale of 1.5 million shares at EUR 15.25 on Euronext Amsterdam, giving the company a market cap of EUR 102.4 million ($130.6 …

    Published on 10/23/2014
  • FINANCIAL NEWS: Quartet raises $17M series A

    Analgesic developer Quartet Medicine (Cambridge, Mass.) raised $17 million in a series A round led by Atlas Venture. Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund also participated. …

    Published on 10/23/2014
  • FINANCIAL NEWS: S1 Biopharma sets IPO range

    S1 Biopharma Inc. (New York, N.Y.) amended its IPO on NASDAQ and plans to sell 2.8 million shares at $12-$14. At $13, the company would raise $35.8 million and be valued at $118.6 million. S1 Biopharma filed to raise up…

    Published on 10/23/2014
  • FINANCIAL NEWS: DBV Technologies launches ADSs

    American Depository Receipts for DBV Technologies S.A. (NASDAQ:DBVT; Euronext:DBV) added $1.26 to $22.90 on NASDAQ Wednesday after the allergy company sold 4.3 million ADSs at $21.64 each in a follow-on that, combined …

    Published on 10/22/2014
  • FINANCIAL NEWS: Forendo closes EUR 12M series A

    Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB; Novo Seeds; …

    Published on 10/22/2014
  • FINANCIAL NEWS: Molecular Partners postpones big Swiss IPO

    Ophthalmic and cancer company Molecular Partners AG (Schlieren, Switzerland) postponed plans for a big IPO on the SIX Swiss Exchange, citing "adverse market conditions." The company had begun bookbuilding on Oct. 8 and …

    Published on 10/22/2014
  • FINANCIAL NEWS: Proteon raises $61.1M in IPO

    Proteon Therapeutics Inc. (NASDAQ:PRTO) closed up $0.03 to $10.03 in its first day of trading Wednesday after raising $61.1 million by selling 6.1 million shares at $10 in an IPO on NASDAQ. The price valued Proteon at $…

    Published on 10/22/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993